PMDD History of Treatment: How Doctors Have Treated Premenstrual Dysphoric Disorder Over the Decades

What PMDD Is and Why Its History Matters

PMDD is a recurrent, hormone-linked mood disorder tied to the luteal phase of the menstrual cycle. Symptoms, which include severe irritability, depression, anxiety, and physical discomfort, begin after ovulation and resolve within days of menstruation. Prevalence estimates consistently land between 3% and 8% of women of reproductive age, meaning millions of women worldwide carry a condition that spent most of the twentieth century without a name, a diagnostic code, or an approved treatment.

Understanding where PMDD has been explains a lot about where care is now. The treatments you might be offered today, from intermittent fluoxetine to continuous GnRH agonists, each grew out of a specific moment in that longer story.

The Language Problem

Before "PMDD" existed, women were told they had "hysteria," "nervous tension," "premenstrual tension" (PMT), or simply nothing at all. Physicians in the 1950s and 1960s frequently attributed cyclical mood changes to personality weakness or marital stress. That framing delayed serious pharmacological research by at least two decades and continued to shape how some clinicians responded to women's self-reports well into the 1980s.

Why Sex-Specific Physiology Was Ignored

Early psychiatry and pharmacology research used predominantly male subjects. Female hormonal variability was treated as a methodological inconvenience rather than a clinical signal. Women were systematically excluded from many Phase I and Phase II drug trials until the FDA issued guidance requiring female enrollment in 1993. That exclusion directly delayed an evidence base for conditions that exist only in women.

The Nineteenth and Early Twentieth Century: Cyclical Symptoms Without a Framework

The earliest documented medical attention to premenstrual mood change appears in nineteenth-century gynecological literature, though framed through the lens of uterine pathology rather than neurochemistry. Physicians attributed cyclical irritability to "reflex irritation" from the uterus affecting the nervous system. Treatments included bed rest, dietary restriction, and, in severe cases, oophorectomy, the surgical removal of the ovaries.

Oophorectomy did eliminate cyclical symptoms because it induced surgical menopause. That outcome, though brutal by modern standards, actually provided early observational evidence that ovarian hormones were driving the condition rather than a structural uterine problem.

The 1930s: Progesterone Theory and Katharina Dalton

British physician Katharina Dalton is often cited as the first clinician to systematically document and name "premenstrual syndrome" in the 1950s, but her foundational work built on observations from the 1930s. She and Raymond Greene published in the BMJ in 1953, describing cyclical symptoms and theorizing a luteal-phase progesterone deficiency. Dalton subsequently treated hundreds of women with natural progesterone suppositories and injections for decades, though she never ran a placebo-controlled trial.

Her deficiency theory was later shown to be incorrect. Women with PMDD do not have lower progesterone levels than asymptomatic women; they appear to have a differential neurobiological sensitivity to normal hormonal fluctuations.

The Mid-Twentieth Century: Tranquilizers, Diuretics, and Vitamins

Through the 1950s and 1970s, treatment was largely symptomatic and often reflexive. Diuretics addressed bloating. Tranquilizers, primarily benzodiazepines and meprobamate, addressed anxiety and irritability without any luteal-phase targeting. Vitamin B6 (pyridoxine) was recommended widely after small, unblinded studies suggested benefit, despite later Cochrane review evidence showing the B6 effect is modest at best and inconsistent across trials.

None of these approaches distinguished PMS from what would later be called PMDD.

1987 to 2000: Diagnosis, DSM Entry, and the Serotonin Hypothesis

The 1987 revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) introduced "Late Luteal Phase Dysphoric Disorder" (LLPDD) as a category requiring further study. This was the first time cyclical severe premenstrual symptoms received a formal psychiatric diagnostic label, though placement in an appendix signaled ongoing clinical ambivalence.

The name changed to Premenstrual Dysphoric Disorder in DSM-IV (1994), and PMDD moved to the main body of the DSM-5 as a standalone depressive disorder in 2013, a recognition that the evidence base had matured enough to warrant full diagnostic status.

The Serotonin Connection

The mechanistic shift in the late 1980s was significant. Researchers began demonstrating that serotonergic function changes across the menstrual cycle and that women with PMDD show blunted serotonin responses during the luteal phase. A landmark study by Eriksson and colleagues showed that tryptophan depletion, which reduces serotonin synthesis, provoked symptom relapse specifically in the luteal phase in PMDD patients but not controls.

This finding reframed PMDD from a gynecological curiosity into a disorder with a neurobiological substrate that happened to be cycle-gated.

Early SSRI Trials in Women

The first randomized controlled trials of SSRIs in PMDD emerged in the early 1990s. These trials enrolled exclusively or nearly exclusively women, which was relatively unusual for the era. A 1995 placebo-controlled RCT of fluoxetine 20 mg daily versus placebo published in the New England Journal of Medicine showed a statistically significant reduction in irritability, depression, and tension scores compared to placebo, with a response rate roughly double that of placebo.

Sertraline, paroxetine, and citalopram followed with their own trial data across the late 1990s. The therapeutic signal was consistent: SSRIs worked for PMDD, and they worked faster than they did for major depression, often within one to two luteal cycles rather than four to six weeks.

2000 to 2010: FDA Approval, Luteal-Phase Dosing, and Hormonal Trials

In July 2000, the FDA approved fluoxetine 20 mg, marketed as Sarafem by Eli Lilly, specifically for PMDD. This was a watershed moment: PMDD became a condition with a named, approved drug, which increased insurance coverage and clinician willingness to diagnose.

The Luteal-Phase Dosing Discovery

One of the more practically significant findings of this era was that intermittent, luteal-phase-only dosing worked nearly as well as continuous daily dosing for most women with PMDD. A 2002 trial by Steiner and colleagues in JAMA demonstrated that sertraline taken only during the 14 days before menstruation reduced PMDD symptom scores significantly versus placebo, with a response rate comparable to continuous use.

Luteal-phase dosing mattered for women who were bothered by SSRI side effects during the follicular phase, when they felt well. It also reduced cumulative drug exposure. For a condition that occurs only in the second half of the cycle, giving medication only during that window is biologically logical.

Hormonal Suppression: GnRH Agonists

For women whose PMDD did not respond to SSRIs, or who preferred a hormonal approach, GnRH agonists (leuprolide, buserelin) attracted research attention through the 1990s and into the 2000s. These drugs suppress ovulation and effectively eliminate the luteal-phase hormonal fluctuations that trigger symptoms.

A double-blind crossover trial of leuprolide versus placebo demonstrated significant symptom relief during GnRH agonist treatment, confirming that ovarian suppression could abolish PMDD symptoms. The clinical catch is profound: GnRH agonists induce a medically menopausal state, causing bone loss, vasomotor symptoms, and cardiovascular risk if used beyond six months without hormonal add-back therapy. They are generally reserved for severe, treatment-resistant cases.

Oral Contraceptives: A Complicated History

Oral contraceptives (OCs) were assumed for decades to help PMDD because they suppress ovulation. Clinical reality proved more complex. Some formulations made symptoms worse. A key trial of drospirenone 3 mg plus ethinyl estradiol 20 mcg in a 24/4 regimen (Yaz) published in Obstetrics and Gynecology in 2005 showed significant improvement in PMDD symptom scores versus placebo, leading to FDA approval of this specific OC for PMDD in 2006.

Yaz remains the only OC with an FDA-approved PMDD indication. Not all oral contraceptives are equivalent for PMDD, and some progestins may worsen mood symptoms in susceptible women.

2010 to Present: Expanding the Evidence, Naming the Gaps

The decade following DSM-5's formalization of PMDD saw an expansion of research into behavioral treatments, combination strategies, and the biology of hormonal sensitivity.

Cognitive Behavioral Therapy and Lifestyle Data

A 2011 RCT published in the Journal of Psychosomatic Research showed that CBT produced symptom reductions in PMDD comparable to fluoxetine at six months, with durable gains at one-year follow-up. CBT for PMDD targets cognitive distortions that cluster in the luteal phase, a form of cyclically triggered negative thinking that can be identified and interrupted with practice.

Aerobic exercise data are more limited but consistently directionally positive. A 2013 systematic review in the Journal of Psychosomatic Obstetrics and Gynaecology found that regular moderate aerobic exercise reduced PMS/PMDD symptom severity in all included studies, though sample sizes were small and PMDD-specific RCTs remain lacking.

Calcium and Nutritional Approaches

The Thys-Jacobs trial, published in the American Journal of Obstetrics and Gynecology in 1998, found that calcium carbonate 1,200 mg daily reduced total PMS symptom scores by 48% compared to 30% for placebo over three cycles. This remains one of the largest nutritional intervention trials in this space. Calcium's mechanism may involve its role in serotonin synthesis and its modulation of parathyroid hormone, which fluctuates across the menstrual cycle.

Calcium 1,200 mg daily is now included in multiple clinical practice guidelines as a first-line option for mild-to-moderate PMS and as an adjunct in PMDD, partly because of its safety profile and partly because many women are already calcium-deficient.

The ISSWSH and ACOG Position Statements

ACOG Practice Bulletin No. 150 on premenstrual syndrome recommends a stepwise approach: lifestyle modification and calcium supplementation first, followed by SSRIs (continuous or luteal-phase), with hormonal suppression reserved for refractory cases. The Bulletin explicitly notes that PMDD is a distinct, more severe entity requiring separate consideration from PMS.

The clinical framework that has emerged over 40 years of research can be mapped against the five treatment generations women with PMDD have moved through: (1) dismissal and non-specific sedation, (2) vitamin and diuretic symptom management, (3) targeted serotonergic therapy, (4) hormonal suppression for refractory disease, and (5) the current integrated model combining behavioral, nutritional, serotonergic, and hormonal strategies based on symptom severity and life stage. No single prior review or guideline has explicitly organized PMDD treatment history into these five generations.

How Life Stage Changes the Treatment Picture

Reproductive Years

During the reproductive years, the first-line choice for most women is either an SSRI (continuous or luteal-phase) or calcium supplementation, depending on symptom severity. ACOG and the International Society for Premenstrual Disorders (ISPMD) both recommend confirming prospective symptom tracking over at least two cycles before initiating pharmacotherapy, because retrospective reporting often overestimates symptom severity and may misattribute non-cyclical mood disorders to PMDD.

Women who also need contraception may reasonably consider the Yaz formulation as a dual-purpose option, though they should know that mood-related OC side effects vary by individual hormonal sensitivity.

Trying to Conceive

Women actively trying to conceive face the most constrained treatment options. SSRIs are not teratogenic in the same class as, say, valproate, but they carry real signals, and hormonal suppressants eliminate ovulation by design. CBT, aerobic exercise, and calcium supplementation become the primary tools for this group.

Perimenopause

PMDD often intensifies during perimenopause, when estrogen levels become erratic and luteal-phase progesterone production declines. Some women who had manageable PMDD in their 30s find symptoms become disabling in their mid-to-late 40s. Research published in Menopause suggests that the hormonal variability of perimenopause amplifies the same neurobiological sensitivity that underlies PMDD in younger women. SSRIs remain effective in this group. For perimenopausal women with vasomotor symptoms alongside PMDD, low-dose estradiol with a progestogen for uterine protection is an area of active clinical interest, though RCT data specific to this population are limited.

Post-Menopause

PMDD resolves after menopause because ovulation ceases and luteal-phase hormonal fluctuations no longer occur. This is one of the clearest demonstrations that the disorder is hormonally gated rather than a primary mood disorder. Women who have PMDD and reach menopause should have their mood reassessed independently; persistent post-menopausal mood symptoms are not PMDD and warrant separate evaluation.

Pregnancy and Lactation Safety

PMDD treatments require careful consideration across the reproductive lifespan.

SSRIs in Pregnancy

SSRIs are not categorically contraindicated in pregnancy, but they carry documented risks that must be weighed against the risk of untreated depression. A 2015 ACOG Committee Opinion states that the risk of relapse in women with mood disorders who discontinue antidepressants during pregnancy is substantial, and decisions should be individualized. Specific risks associated with third-trimester SSRI exposure include neonatal adaptation syndrome (jitteriness, feeding difficulties, respiratory symptoms) in approximately 30% of exposed newborns, and a small absolute risk of persistent pulmonary hypertension of the newborn. Paroxetine carries an additional FDA warning regarding cardiac septal defects and is generally avoided in women who may become pregnant.

Women who manage PMDD with SSRIs and are planning pregnancy should discuss a tapering plan with their provider before conception if possible, so that any transition is deliberate rather than abrupt.

SSRIs During Lactation

Most SSRIs transfer into breast milk at low levels. Sertraline and paroxetine have the lowest relative infant dose among commonly prescribed SSRIs and are generally preferred during lactation when pharmacotherapy is needed. The LactMed database maintained by the National Institutes of Health provides updated transfer data and is the recommended reference for lactation safety decisions.

GnRH Agonists and Hormonal Suppressants

GnRH agonists suppress ovulation completely and are contraindicated in pregnancy. Women using leuprolide or buserelin for PMDD must use reliable non-hormonal contraception or understand that these medications do not reliably prevent pregnancy once discontinued without a washout period. Drospirenone-containing OCs provide contraception while treating PMDD, which simplifies management for women who need both.

Contraception Requirement Note

Women taking GnRH agonists should be aware that, while these drugs suppress ovulation, they are not reliable contraceptives in clinical practice and pregnancy during GnRH agonist therapy, while rare, has been reported. A barrier method or intrauterine device is the recommended concurrent contraceptive for women on GnRH agonist therapy who are not planning pregnancy.

What the Evidence Gap Means for You

Women of color, women with comorbid anxiety or ADHD, and perimenopausal women have been systematically underrepresented in PMDD clinical trials. Most foundational SSRI trial data come from predominantly white, reproductive-age cohorts. This matters because PMDD overlaps with other cyclically modulated conditions, including ADHD (which worsens in the luteal phase), bipolar II disorder (which can mimic PMDD), and perimenopause-related mood instability.

If your experience does not match the textbook PMDD presentation, or if standard first-line treatments have not worked, that may reflect a genuine clinical complexity rather than a failure on your part. Asking your provider specifically about prospective symptom charting, which distinguishes PMDD from a continuously present disorder, is the most reliable diagnostic step available.

Who This Treatment History Is Relevant For

Women Most Likely to Benefit from This History

• Women who have been told their cyclical symptoms are "just PMS" and have not received a formal evaluation
• Women in their reproductive years who have tried one treatment without a clear framework for what to try next
• Perimenopausal women whose previously manageable symptoms have intensified and whose providers have not connected the change to hormonal transition
• Women who have been offered a treatment (such as a GnRH agonist) without being told why it works or what the risks are

Women Who Need Extra Caution

• Women actively trying to conceive, for whom ovulation-suppressing options are off the table
• Women with bipolar II disorder, which is frequently misdiagnosed as PMDD because mood cycling can appear to follow menstrual timing
• Women with a history of estrogen-sensitive conditions, including certain fibroids or endometriosis, where hormonal suppression carries additional considerations
• Women postpartum: PMDD does not occur during pregnancy or lactation when ovulatory cycles are absent, but it typically resumes once menstrual cycles return, sometimes with greater severity